SINGAPORE - Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) requested a hearing before the Nasdaq Hearings Panel on Wednesday in response to a delisting determination from Nasdaq.
The biomedical company received a staff determination letter on Tuesday notifying it that its securities will be scheduled for delisting from The Nasdaq Capital Market due to failure to meet the minimum bid price requirement of $1.00 per share.
Cuprina initially received a non-compliance notice on November 26, 2025, after its closing bid price fell below the minimum requirement for 30 consecutive business days. The stock has declined 91% over the past year, though it surged 53% in the last week alone, currently trading at $2.51 with a market capitalization of just $8.85 million.
The company completed a reverse stock split on Tuesday and filed its hearing request on Wednesday. The hearing request stays the suspension of the company’s securities pending the panel’s decision.
Cuprina’s securities will continue to trade on Nasdaq during the hearing process.
The Singapore-based company develops products for chronic wounds, infertility, medical waste recycling, and cosmeceuticals.
In other recent news, Cuprina announced plans to implement a 1-for-8 reverse stock split of its Class A and Class B ordinary shares to regain compliance with Nasdaq listing rules.
